Journal article
Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients
RSC Lee, MA Redoblado-Hodge, SL Naismith, DF Hermens, MA Porter, IB Hickie
Psychological Medicine | CAMBRIDGE UNIV PRESS | Published : 2013
Abstract
Cognitive remediation (CR) is an effective treatment for several psychiatric disorders. To date, there have been no published studies examining solely first-episode psychiatric cohorts, despite the merits demonstrated by early intervention CR studies. The current study aimed to assess the effectiveness of CR in patients with a first-episode of either major depression or psychosis. Method Fifty-five patients (mean age = 22.8 years, s.d. = 4.3) were randomly assigned to either CR (n = 28) or treatment as usual (TAU; n = 27). CR involved once-weekly 2-h sessions for a total of 10 weeks. Patients were comprehensively assessed before and after treatment. Thirty-six patients completed the study, a..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This research was supported by a National Health and Medical Research Council (NHMRC) Program Grant (No. 350241) and an NHMRC Australia Fellowship awarded (No. 511921) to I. B. H. S.LN. was funded by an NHMRC Clinical Research Fellowship (No. 402864). I.B.H. has led projects for health professionals and the community supported by governmental, community agency, and drug industry partners (Wyeth, Eli Lilly, Servier, Pfizer, AstraZeneca) for the identification and management of depression and anxiety. He has served on advisory boards convened by the drug industry in relation to specific antidepressants, including nefazodone, duloxetine, and desvenlafaxine, and has participated in a multicenter clinical trial of agomelatine effects on sleep architecture in depression. He has participated in Servier-sponsored educational programs related to circadian-based therapies. D. F. H. has previously received honoraria for educational seminars from Janssen-Cilag. M. A. R. H. has received financial support from Eli Lilly for a multisite trial of cognitive remediation in psychosis, and is a co-investigator in an Australian Rotary-funded project investigating the synergistic effects of cognitive remediation and vocational training in psychosis. She was also a co-investigator in a drug trial with Novartis Pharmaceutical who sponsored overseas travel in 2011, and was also involved in NHMRC-funded trials in psychosis.